The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 22, 2024
Filed:
Dec. 16, 2019
Fundación Para LA Investigación Del Hospital Universitario LA Fe DE LA Comunidad Valenciana, Valencia, ES;
Maastricht University, Maastricht, NL;
David Hervàs Marin, Valencia, ES;
Ana Santaballa Beltràn, Valencia, ES;
Carmen Salvador Coloma, Valencia, ES;
Rubèn Carrero Garcìa, Valencia, ES;
Rafael Sanchez Sanchez, Valencia, ES;
Akaitz Dorronsoro Gonzàlez, Valencia, ES;
Imelda Ontoria Oviedo, Valencia, ES;
Sandra Tejedor Gascòn, Valencia, ES;
Estaban Peiró Molina, Valencia, ES;
Amparo Hernándiz Martinez, Valencia, ES;
Hernán González-King, Valencia, ES;
María Ciria Calduch, Valencia, ES;
Delia Castellano Izquierdo, Valencia, ES;
Joaquín Panadero Romero, Valencia, ES;
Jose Anastasio Montero Argudo, Valencia, ES;
Pilar Sepúlveda Sanchis, Valencia, ES;
Nahuel A. García, Valencia, ES;
Florian Caiment, Maastricht, NL;
Jos Kleinjans, Maastricht, NL;
Stephane Heymans, Maastricht, NL;
Jort Merken, Maastricht, NL;
Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, ES;
Maastricht University, Maastricht, NL;
Abstract
The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p and miRNA-4732-3p, in a biological sample isolated from the patient. The present invention also refers to said set of 10 circulating miRNAs for its use as biomarker of prediction of cardiotoxicity risk in cancer patients receiving, or susceptible to receive, anthracyclines chemotherapy. Finally, a method for the prevention of cardiotoxicity, in patients receiving or susceptible to receive anthracyclines chemotherapy, that comprises modulating the expression levels of the set of said 10 circulating miRNAS is contemplated.